Fig. 1From: Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapyECM-degrading photothermal nanoagonist (dNAc)-mediated mild NIR-II PTT-augmented CDT-immunotherapy. a Schematic illustration of synthesis route of dNAc via hydration-sonication and surface modification. b Schematic illustration of NIR-II photoactivation of dNAc for mild photothermal effect-augmented CDT-immunotherapyBack to article page